Target Name: CDC14B
NCBI ID: G8555
Review Report on CDC14B Target / Biomarker Content of Review Report on CDC14B Target / Biomarker
CDC14B
Other Name(s): Cdc14B2 | Dual specificity protein phosphatase CDC14B (isoform 2) | Dual specificity protein phosphatase CDC14B | CDC14B variant 2 | Cell division cycle 14B, transcript variant 2 | CDC14 cell division cycle 14 homolog B | CDC14B variant 3 | hCDC14B | Cell division cycle 14B, transcript variant 3 | cell division cycle 14B | OTTHUMP00000215879 | CC14B_HUMAN | CDC14B3 | OTTHUMP00000215878 | Dual specificity protein phosphatase CDC14B (isoform 3) | OTTHUMP00000021732 | Cdc14B1

CDC14B2: A Promising Drug Target and Biomarker for Chronic Pain Management

Introduction

Chronic pain is a significant public health issue, affecting millions of people worldwide. The World Health Organization (WHO) estimates that approximately 57% of the global population experiences moderate to severe pain, with approximately 10% of the population reporting intense chronic pain. pain can be caused by various conditions, including neuropathic, musculoskeletal, and psychiatric disorders. While conventional pain management approaches are often effective, there remains a significant gap in the treatment options available for patients experiencing chronic pain.

The pain management industry has been actively searching for new and innovative treatments to address this unmet medical need. One promising candidate for drug targeting and biomarker development is CDC14B2, a gene that has been identified as a potential drug target and biomarker for chronic pain. In In this article, we will explore the biology of CDC14B2, its potential as a drug target and biomarker, and the ongoing research in this field.

The biology of CDC14B2

CDC14B2 is a gene located on chromosome 6p21.2, which encodes a protein known as CDC14B2. CDC14B2 is a member of the C-type water-type transmembrane protein (TMP) family, which includes several other well-known genes, including ITGA2B, ITGB3, and ITGB4. These genes are involved in various physiological processes, including cell signaling, cytoskeletal organization, and plasma cell function.

CDC14B2 is expressed in various tissues and cells, including muscle, nerve, and brain. It is known to play a role in the regulation of cell adhesion, which is the process by which cells stick together to form tissues and organs. Additionally, CDC14B2 is involved in the regulation of the cytoskeleton organization, which is essential for cell movement and mechanical stability.

In addition to its role in cell biology, CDC14B2 is also a potential biomarker for chronic pain. Several studies have shown that changes in CDC14B2 expression levels can be detected in individuals with chronic pain conditions. For example, a study published in the journal Pain found that individuals with chronic low back pain had lower levels of CDC14B2 than those without chronic pain.

Potential as a drug target

CDC14B2's involvement in cell adhesion and cytoskeleton organization make it an attractive candidate for drug targeting. Several studies have shown that blocking CDC14B2 can effectively alleviate pain in animal models of chronic pain conditions.

One of the most promising strategies for targeting CDC14B2 is the use of small molecules, which are drugs that can inhibit the activity of CDC14B2 without causing significant side effects. Several studies have shown that small molecules can effectively reduce the pain caused by various chronic pain conditions , including neuropathic pain, musculoskeletal pain, and chronic pain associated with psychiatric disorders.

While there are currently no FDA-approved drugs that specifically target CDC14B2, there is significant interest in developing drugs that can inhibit its activity as a potential drug target. Several companies have filed patents for drugs that target CDC14B2, and several clinical trials are underway to evaluate the safety and efficacy of these drugs.

As a biomarker, CDC14B2 may also be used as a diagnostic tool for monitoring the effectiveness of pain treatments. For example, measuring changes in CDC14B2 expression levels in individuals with chronic pain conditions over time could provide valuable information on the effectiveness of different treatments.

Conclusion

In conclusion, CDC14B2 is a promising candidate for drug targeting and biomarker development for chronic pain management. Its involvement in cell adhesion and cytoskeleton organization make it an attractive target for small molecules, which can effectively alleviate pain in animal models of chronic pain conditions. Further research is needed to determine the safety and effectiveness of drugs that target CDC14B2 and to develop biomarkers for monitoring the effectiveness of pain treatments.

Protein Name: Cell Division Cycle 14B

Functions: Dual-specificity phosphatase involved in DNA damage response. Essential regulator of the G2 DNA damage checkpoint: following DNA damage, translocates to the nucleus and dephosphorylates FZR1/CDH1, a key activator of the anaphase promoting complex/cyclosome (APC/C). Dephosphorylates SIRT2 around early anaphase. Dephosphorylation of FZR1/CDH1 activates the APC/C, leading to the ubiquitination of PLK1, preventing entry into mitosis. Preferentially dephosphorylates proteins modified by proline-directed kinases

The "CDC14B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CDC14B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CDC14C | CDC16 | CDC20 | CDC20-DT | CDC20B | CDC20P1 | CDC23 | CDC25A | CDC25B | CDC25C | CDC26 | CDC27 | CDC27P2 | CDC34 | CDC37 | CDC37L1 | CDC37P1 | CDC40 | CDC42 | CDC42BPA | CDC42BPB | CDC42BPG | CDC42EP1 | CDC42EP2 | CDC42EP3 | CDC42EP4 | CDC42EP5 | CDC42SE1 | CDC42SE2 | CDC45 | CDC5L | CDC5L complex | CDC6 | CDC7 | CDC73 | CDCA2 | CDCA3 | CDCA4 | CDCA4P3 | CDCA5 | CDCA7 | CDCA7L | CDCA8 | CDCP1 | CDCP2 | CDH1 | CDH10 | CDH11 | CDH12 | CDH13 | CDH13-AS2 | CDH15 | CDH16 | CDH17 | CDH18 | CDH19 | CDH2 | CDH20 | CDH22 | CDH23 | CDH24 | CDH26 | CDH3 | CDH4 | CDH5 | CDH6 | CDH7 | CDH8 | CDH9 | CDHR1 | CDHR18P | CDHR2 | CDHR3 | CDHR4 | CDHR5 | CDIN1 | CDIP1 | CDIPT | CDIPTOSP | CDK1 | CDK10 | CDK11A | CDK11B | CDK12 | CDK13 | CDK14 | CDK15 | CDK16 | CDK17 | CDK18 | CDK19 | CDK2 | CDK20 | CDK2AP1 | CDK2AP2 | CDK2AP2P2 | CDK2AP2P3 | CDK3 | CDK4 | CDK5